It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Clinical Trials

Drug Treatment Study for Patients with Advanced Cancers

A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Treatment Study For Patients With Advanced BRAFV600 Mutant Melanoma

Dabrafenib + trametinib followed by ipilimumab + nivolumab at progression or ipilimumab + nivolumab followed by dabrrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma.

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer

A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.

Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma

Nivolumab plus ipilimumab plus sargramostin versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma.